Qiming U.S. Ventures Management’s Jasper Therapeutics JSPR Stock Holding History

Qiming U.S. Ventures Management’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$2.21M	Hold	928,964	–	–	3.97%	3
2025 Q2	$5.16M	Hold	928,964	–	–	21.83%	2
2025 Q1	$3.99M	Hold	928,964	–	–	17.29%	3
2024 Q4	$19.9M	Hold	928,964	–	–	38.83%	1
2024 Q3	$17.5M	Hold	928,964	–	–	34.02%	2
2024 Q2	$21.1M	Hold	928,964	–	–	40.07%	1
2024 Q1	$27.3M	Buy	928,964 +76,999	+9%	+$1.37M	30.41%	2
2023 Q4	$6.72M	Hold	851,965	–	–	6.16%	5
2023 Q3	$5.96M	Hold	851,965	–	–	7.92%	5
2023 Q2	$11.7M	Hold	851,965	–	–	12.26%	3
2023 Q1	$15.4M	Buy	851,965 +266,667	+46%	+$4.93M	18.66%	3
2022 Q4	$2.83M	Hold	585,298	–	–	3.74%	6
2022 Q3	$4.62M	Hold	585,298	–	–	6.71%	6
2022 Q2	$11.3M	Hold	585,298	–	–	15.68%	3
2022 Q1	$20.8M	Hold	585,298	–	–	19.52%	3
2021 Q4	$45.9M	Buy	+585,298	New	+$54.8M	21.14%	2

Other funds holding JSPR

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Qiming U.S. Ventures Management's JSPR Position: Q3 2025 in Review

Qiming U.S. Ventures Management held its Jasper Therapeutics (JSPR) position steady in Q3 2025 at 928,964 shares worth $2.21M. The position accounts for 3.97% of the portfolio, ranked #3.

Qiming U.S. Ventures Management first reported a position in JSPR in Q4 2021 and has held it in 16 quarters since. The position peaked at $45.9M in Q4 2021. 60 funds tracked by Wall St. Rank hold JSPR as of Q3 2025.

Qiming U.S. Ventures Management held 928,964 shares of Jasper Therapeutics worth $2.21M as of Q3 2025.
Qiming U.S. Ventures Management left its Jasper Therapeutics share count unchanged in Q3 2025.
Jasper Therapeutics made up 3.97% of Qiming U.S. Ventures Management's portfolio in Q3 2025, its #3 holding.
Qiming U.S. Ventures Management first reported a position in Jasper Therapeutics in Q4 2021 and has held it in 16 quarters since.
Qiming U.S. Ventures Management's Jasper Therapeutics position peaked at $45.9M in Q4 2021.
60 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q3 2025.

Based on Qiming U.S. Ventures Management's 13F filing for Q3 2025, filed 10 Nov 2025.